NASDAQ: MTVA
MetaVia Inc.CIK 0001638287 · SIC 2834 · Pharmaceutical Preparations
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (PATH 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade MTVA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
MetaVia stockholders approve reverse stock split at 1-for-5 to 1-for-22 ratio
3 material changes detected. Sign up free to read the summary.
MetaVia reports 9.1% weight loss in Phase 1 obesity trial for DA-1726, advances pipeline
4 material changes detected. Sign up free to read the summary.
MetaVia presents Phase 1 data on dual-receptor obesity/liver drug DA-1726 at EASL
2 material changes detected. Sign up free to read the summary.
MetaVia obesity and diabetes drug data accepted for ADA 2026 conference presentations
2 material changes detected. Sign up free to read the summary.
net income -$3.8M. MetaVia removes material weakness disclosures; vanoglipel Phase 2a timeline slips one year
5 material changes detected. Sign up free to read the summary.
net income -$13.0M. MetaVia extends cash runway to Q4 2026 via + equity raises; warrant overhang drops 53.0%
4 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 6, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations (Unaudited)
(Unaudited - In thousands, except share and per share amounts)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses | ||||
| Research and development | 3,478 | 2,320 | 5,579 | 4,647 |
| General and administrative | 1,907 | 1,981 | 3,831 | 3,540 |
| Total operating expenses | 5,385 | 4,301 | 9,410 | 8,187 |
| Loss from operations | (5,385) | (4,301) | (9,410) | (8,187) |
| Other income (expense) | ||||
| (Loss) gain from change in fair value of warrant liabilities | (4) | 160 | 113 | 247 |
| Interest income, net | 73 | 146 | 158 | 274 |
| Total other income | 69 | 306 | 271 | 521 |
| Loss before income taxes | (5,316) | (3,995) | (9,139) | (7,666) |
| Provision for income taxes | — | — | — | — |
| Net loss | (5,316) | (3,995) | (9,139) | (7,666) |
| Loss per share of common stock, basic and diluted | (0.90) | (2.87) | (1.69) | (6.59) |
| Weighted average shares of common stock, basic and diluted | 5,931,875 | 1,389,753 | 5,398,683 | 1,162,692 |
Condensed Consolidated Balance Sheets (Unaudited)
(Unaudited - In thousands, except share and per share amounts)
| Description | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | 12,634 | 10,278 |
| Prepaid expenses and other current assets | 433 | 597 |
| Total current assets | 13,067 | 10,875 |
| Property and equipment, net | 8 | 17 |
| Right-of-use asset | 175 | 210 |
| Other assets | 21 | 21 |
| Total assets | 13,271 | 11,123 |
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable | 921 | 1,060 |
| Clinical trial accrued liabilities | 2,825 | 79 |
| Accrued expenses and other current liabilities | 606 | 993 |
| Warrant liabilities | 23 | 136 |
| Related party payable | 1,897 | 3,312 |
| Lease liability, short-term | 74 | 68 |
| Total current liabilities | 6,346 | 5,648 |
| Lease liability, long-term | 103 | 142 |
| Total liabilities | 6,449 | 5,790 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.001 par value per share; 10,000,000 shares authorized and no shares issued or outstanding as of June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value per share, 100,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 6,575,656 and 2,308,294 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 7 | 2 |
| Additional paid–in capital | 164,784 | 154,161 |
| Accumulated deficit | (157,969) | (148,830) |
| Total stockholders’ equity | 6,822 | 5,333 |
| Total liabilities and stockholders’ equity | 13,271 | 11,123 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Unaudited - In thousands)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Operating activities | ||
| Net loss | (9,139) | (7,666) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 230 | 243 |
| Non-cash professional services expenses | 144 | — |
| Non-cash lease charge (credit) | 2 | (1) |
| Depreciation | 9 | 9 |
| Gain from change in fair value of warrant liabilities | (113) | (247) |
| Change in operating assets and liabilities | ||
| Prepaid expenses and other assets | 164 | (671) |
| Accounts payable | (261) | (1,348) |
| Accrued and other liabilities | 944 | 1,795 |
| Net cash used in operating activities | (8,020) | (7,886) |
| Investing activities | ||
| Purchases of property and equipment | — | (2) |
| Net cash used in investing activities | — | (2) |
| Financing activities | ||
| Proceeds from the issuance of common stock and warrants under an underwritten public offering | 9,316 | — |
| Payment of issuance costs in connection with the sale of common stock and warrants under an underwritten public offering | (2,179) | — |
| Proceeds from the issuance of common stock under an at the market offering agreement | 913 | — |
| Payment of issuance costs in connection with the sale of common stock under an at the market offering agreement | (94) | — |
| Proceeds from the issuance of common stock and warrants under the securities purchase agreements from a private placement offering | — | 9,996 |
| Payment of issuance costs in connection with the sale of common stock and warrants under the securities purchase agreements from a private placement offering | — | (530) |
| Proceeds from exercise of warrants | 2,420 | 6 |
| Payment of employee withholding taxes related to shares withheld from vested restricted stock units | — | (12) |
| Net cash provided by financing activities | 10,376 | 9,460 |
| Net increase in cash and cash equivalents | 2,356 | 1,572 |
| Cash and cash equivalents at beginning of period | 10,278 | 16,017 |
| Cash and cash equivalents at end of period | 12,634 | 17,589 |
| Supplemental non-cash investing and financing transactions | ||
| Unpaid issuance costs | 122 | 344 |
Amounts as printed on the EDGAR/iXBRL face — (Unaudited - In thousands, except share and per share amounts); (Unaudited - In thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗